Calamos Advisors LLC lowered its position in shares of Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR) by 54.5% in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 5,000 shares of the biotechnology company’s stock after selling 6,000 shares during the period. Calamos Advisors LLC’s holdings in Arrowhead Pharmaceuticals were worth $317,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently made changes to their positions in ARWR. Public Employees Retirement System of Ohio lifted its position in shares of Arrowhead Pharmaceuticals by 118.9% in the 2nd quarter. Public Employees Retirement System of Ohio now owns 22,069 shares of the biotechnology company’s stock worth $585,000 after purchasing an additional 11,985 shares during the period. Northern Trust Corp lifted its position in shares of Arrowhead Pharmaceuticals by 5.1% in the 2nd quarter. Northern Trust Corp now owns 1,257,200 shares of the biotechnology company’s stock worth $33,315,000 after purchasing an additional 61,133 shares during the period. Parametric Portfolio Associates LLC lifted its position in shares of Arrowhead Pharmaceuticals by 60.1% in the 2nd quarter. Parametric Portfolio Associates LLC now owns 80,302 shares of the biotechnology company’s stock worth $2,128,000 after purchasing an additional 30,147 shares during the period. BlackRock Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 94.5% in the 2nd quarter. BlackRock Inc. now owns 14,841,966 shares of the biotechnology company’s stock worth $393,313,000 after purchasing an additional 7,210,892 shares during the period. Finally, Vanguard Group Inc. lifted its position in shares of Arrowhead Pharmaceuticals by 75.4% in the 2nd quarter. Vanguard Group Inc. now owns 8,637,838 shares of the biotechnology company’s stock worth $228,903,000 after purchasing an additional 3,712,392 shares during the period. 69.81% of the stock is owned by institutional investors and hedge funds.
Shares of ARWR stock opened at $43.26 on Tuesday. The firm has a market capitalization of $4.26 billion, a PE ratio of 62.70 and a beta of 1.97. The company has a 50 day moving average price of $56.69 and a 200-day moving average price of $43.15. Arrowhead Pharmaceuticals Inc has a 52 week low of $12.72 and a 52 week high of $73.72.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Monday, November 25th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.14 by ($0.03). Arrowhead Pharmaceuticals had a return on equity of 32.30% and a net margin of 40.27%. The business had revenue of $43.29 million during the quarter, compared to analysts’ expectations of $36.97 million. Sell-side analysts forecast that Arrowhead Pharmaceuticals Inc will post -0.15 EPS for the current year.
In other news, CEO Christopher Richard Anzalone sold 37,967 shares of the business’s stock in a transaction on Monday, December 2nd. The shares were sold at an average price of $69.15, for a total value of $2,625,418.05. Following the transaction, the chief executive officer now owns 2,116,160 shares of the company’s stock, valued at $146,332,464. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of the business’s stock in a transaction on Monday, January 6th. The stock was sold at an average price of $60.11, for a total transaction of $1,202,200.00. Following the completion of the transaction, the chief financial officer now directly owns 403,592 shares in the company, valued at approximately $24,259,915.12. The disclosure for this sale can be found here. Insiders have sold 248,518 shares of company stock worth $15,591,357 in the last ninety days. Insiders own 4.80% of the company’s stock.
ARWR has been the subject of several research reports. Chardan Capital reiterated a “buy” rating and issued a $81.00 price target (up from $45.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, November 29th. S&P Equity Research reiterated a “buy” rating on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, November 26th. B. Riley reiterated a “buy” rating and issued a $83.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Friday, January 24th. Piper Jaffray Companies increased their price target on shares of Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the stock an “overweight” rating in a research note on Monday, December 9th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $50.00 price objective (up from $24.00) on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, November 19th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and five have issued a buy rating to the stock. Arrowhead Pharmaceuticals currently has an average rating of “Hold” and an average price target of $61.14.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company’s pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
Recommended Story: Profit Margin
Receive News & Ratings for Arrowhead Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.